全文获取类型
收费全文 | 3277643篇 |
免费 | 275119篇 |
国内免费 | 13145篇 |
专业分类
耳鼻咽喉 | 45606篇 |
儿科学 | 103157篇 |
妇产科学 | 85293篇 |
基础医学 | 523980篇 |
口腔科学 | 89320篇 |
临床医学 | 291624篇 |
内科学 | 562909篇 |
皮肤病学 | 91386篇 |
神经病学 | 277053篇 |
特种医学 | 131618篇 |
外国民族医学 | 226篇 |
外科学 | 513436篇 |
综合类 | 101017篇 |
一般理论 | 2191篇 |
预防医学 | 268545篇 |
眼科学 | 76105篇 |
药学 | 233576篇 |
22篇 | |
中国医学 | 9604篇 |
肿瘤学 | 159239篇 |
出版年
2021年 | 43668篇 |
2020年 | 34334篇 |
2019年 | 57301篇 |
2018年 | 69757篇 |
2017年 | 53042篇 |
2016年 | 58543篇 |
2015年 | 72970篇 |
2014年 | 107697篇 |
2013年 | 173102篇 |
2012年 | 88920篇 |
2011年 | 88308篇 |
2010年 | 115717篇 |
2009年 | 120512篇 |
2008年 | 74986篇 |
2007年 | 77662篇 |
2006年 | 88705篇 |
2005年 | 83756篇 |
2004年 | 85534篇 |
2003年 | 76393篇 |
2002年 | 66000篇 |
2001年 | 106874篇 |
2000年 | 99393篇 |
1999年 | 96915篇 |
1998年 | 59402篇 |
1997年 | 57130篇 |
1996年 | 54834篇 |
1995年 | 55742篇 |
1994年 | 49735篇 |
1993年 | 46445篇 |
1992年 | 67908篇 |
1991年 | 64557篇 |
1990年 | 61515篇 |
1989年 | 60610篇 |
1988年 | 55539篇 |
1987年 | 54106篇 |
1986年 | 51296篇 |
1985年 | 51007篇 |
1984年 | 46555篇 |
1983年 | 42406篇 |
1982年 | 40404篇 |
1981年 | 38002篇 |
1980年 | 35921篇 |
1979年 | 37478篇 |
1978年 | 33133篇 |
1977年 | 31002篇 |
1976年 | 27754篇 |
1975年 | 26794篇 |
1974年 | 27072篇 |
1973年 | 26076篇 |
1972年 | 24581篇 |
排序方式: 共有10000条查询结果,搜索用时 218 毫秒
1.
Tyler B. Kratzer MPH Ahmedin Jemal DVM PhD Kimberly D. Miller MPH Sarah Nash PhD Charles Wiggins PhD Diana Redwood PhD Robert Smith PhD Rebecca L. Siegel MPH 《CA: a cancer journal for clinicians》2023,73(2):120-146
American Indian and Alaska Native (AIAN) individuals are diverse culturally and geographically but share a high prevalence of chronic illness, largely because of obstacles to high-quality health care. The authors comprehensively examined cancer incidence and mortality among non-Hispanic AIAN individuals, compared with non-Hispanic White individuals for context, using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Overall cancer rates among AIAN individuals were 2% higher than among White individuals for incidence (2014 through 2018, confined to Purchased/Referred Care Delivery Area counties to reduce racial misclassification) but 18% higher for mortality (2015 through 2019). However, disparities varied widely by cancer type and geographic region. For example, breast and prostate cancer mortality rates are 8% and 31% higher, respectively, in AIAN individuals than in White individuals despite lower incidence and the availability of early detection tests for these cancers. The burden among AIAN individuals is highest for infection-related cancers (liver, stomach, and cervix), for kidney cancer, and for colorectal cancer among indigenous Alaskans (91.3 vs. 35.5 cases per 100,000 for White Alaskans), who have the highest rates in the world. Steep increases for early onset colorectal cancer, from 18.8 cases per 100,000 Native Alaskans aged 20–49 years during 1998 through 2002 to 34.8 cases per 100,000 during 2014 through 2018, exacerbated this disparity. Death rates for infection-related cancers (liver, stomach, and cervix), as well as kidney cancer, were approximately two-fold higher among AIAN individuals compared with White individuals. These findings highlight the need for more effective strategies to reduce the prevalence of chronic oncogenic infections and improve access to high-quality cancer screening and treatment for AIAN individuals. Mitigating the disparate burden will require expanded financial support of tribal health care as well as increased collaboration and engagement with this marginalized population. 相似文献
2.
Dimitrios Moris MD MSc PhD Manisha Palta MD Charles Kim MD Peter J. Allen MD Michael A. Morse MD Michael E. Lidsky MD 《CA: a cancer journal for clinicians》2023,73(2):198-222
Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver tumor and remains a fatal malignancy in the majority of patients. Approximately 20%–30% of patients are eligible for resection, which is considered the only potentially curative treatment; and, after resection, a median survival of 53 months has been reported when sequenced with adjuvant capecitabine. For the 70%–80% of patients who present with locally unresectable or distant metastatic disease, systemic therapy may delay progression, but survival remains limited to approximately 1 year. For the past decade, doublet chemotherapy with gemcitabine and cisplatin has been considered the most effective first-line regimen, but results from the recent use of triplet regimens and even immunotherapy may shift the paradigm. More effective treatment strategies, including those that combine systemic therapy with locoregional therapies like radioembolization or hepatic artery infusion, have also been developed. Molecular therapies, including those that target fibroblast growth factor receptor and isocitrate dehydrogenase, have recently received US Food and Drug Administration approval for a defined role as second-line treatment for up to 40% of patients harboring these actionable genomic alterations, and whether they should be considered in the first-line setting is under investigation. Furthermore, as the oncology field seeks to expand indications for immunotherapy, recent data demonstrated that combining durvalumab with standard cytotoxic therapy improved survival in patients with ICC. This review focuses on the current and future strategies for ICC treatment, including a summary of the primary literature for each treatment modality and an algorithm that can be used to drive a personalized and multidisciplinary approach for patients with this challenging malignancy. 相似文献
3.
Laura Ashley PhD Claire Surr PhD Rachael Kelley RMN PhD Mollie Price PhD Alys Wyn Griffiths PhD Nicole R. Fowler MHSA PhD Dana E. Giza MD Richard D. Neal MBChB FRCGP PhD Charlene Martin PhD Jane B. Hopkinson RGN PhD Anita O’Donovan PhD William Dale MD PhD Bogda Koczwara BMBS MBioethics Katie Spencer MB BChir FRCR PhD Lynda Wyld MBChB FRCS PhD 《CA: a cancer journal for clinicians》2023,73(3):320-338
As many countries experience population aging, patients with cancer are becoming older and have more preexisting comorbidities, which include prevalent, age-related, chronic conditions such as dementia. People living with dementia (PLWD) are vulnerable to health disparities, and dementia has high potential to complicate and adversely affect care and outcomes across the cancer trajectory. This report offers an overview of dementia and its prevalence among patients with cancer and a summary of the research literature examining cancer care for PLWD. The reviewed research indicates that PLWD are more likely to have cancer diagnosed at an advanced stage, receive no or less extensive cancer treatment, and have poorer survival after a cancer diagnosis. These cancer disparities do not necessarily signify inappropriately later diagnosis or lower treatment of people with dementia as a group, and they are arguably less feasible and appropriate targets for care optimization. The reviewed research indicates that PLWD also have an increased risk of cancer-related emergency presentations, lower quality processes of cancer-related decision making, accessibility-related barriers to cancer investigations and treatment, higher experienced treatment burden and higher caregiver burden for families, and undertreated cancer-related pain. The authors propose that optimal cancer care for PLWD should focus on proactively minimizing these risk areas and thus must be highly person-centered, with holistic decision making, individualized reasonable adjustments to practice, and strong inclusion and support of family carers. Comprehensive recommendations are made for clinical practice and future research to help clinicians and providers deliver best and equitable cancer care for PLWD and their families. 相似文献
4.
Adam H. Fox MD MS Mizuki Nishino MD Raymond U. Osarogiagbon MBBS M. Patricia Rivera MD Lauren S. Rosenthal MPH Robert A. Smith PhD Farhood Farjah MD Lynette M. Sholl MD Gerard A. Silvestri MD MS Bruce E. Johnson MD 《CA: a cancer journal for clinicians》2023,73(4):358-375
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios. 相似文献
5.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
6.
7.
8.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
9.
Osnat Bairey MD Alisa Taliansky MD Amir Glik MD Alexandra Amiel MD Shlomit Yust-Katz MD Ronit Gurion MD Miri Zektser MD Tzvika Porges MD Nadav Sarid MD Netanel A. Horowitz MD Tzahala Tzuk Shina MD Eyal Lebel MD Amos Cohen MD Karyn Revital Geiger MD Pia Raanani MD Ofir Wolach MD Tali Siegal MD 《Cancer》2023,129(24):3905-3914